Independent Due Diligence and Feasibility Assessment for Military Domestic Pharmaceutical Manufacturing and Supply Chain Resilience

An urgent and critical initiative has been launched to safeguard the Department of Defense’s supply chain for military-essential medications by establishing a domestic manufacturing base for Active Pharmaceutical Ingredients and Key Starting Materials, which are currently almost entirely imported from foreign sources. This poses a severe national security risk, prompting immediate action under the authority of FAR 16.507-6(b)(1) to pursue a sole source procurement due to the unusual and compelling urgency of securing these life-critical medical resources without foreign dependency. The effort requires comprehensive, independent technical, regulatory, and economic due diligence to evaluate and validate viable domestic manufacturing solutions capable of rapidly meeting the DoD’s needs. The contract, titled Independent Due Diligence and Feasibility Assessment for Military Domestic Pharmaceutical Manufacturing and Supply Chain Resilience with solicitation number HT940226F0008, is being managed by the Defense Health Agency under the Department of Defense and is targeted at delivering a strategic roadmap and financial underwriting analysis to enable rapid domestic production capacity. Work will be performed in Arlington, Virginia, with the prime point of contact based in Aurora, Colorado. The NAICS code 541519 indicates this is a professional, scientific, and technical services contract focused on research and development in the pharmaceutical sector. The goal is not merely assessment but actionable deployment—ensuring the military can maintain uninterrupted access to essential medicines during peacetime and conflict by eliminating reliance on vulnerable overseas suppliers.